Identification of small molecule inhibitors of RANKL and TNF signalling as anti-inflammatory and antiresorptive agents in mice

Emmanuel Coste, Iain R Greig, Patrick Mollat, Lorraine Rose, Mohini Gray, Stuart H Ralston, Rob J van 't Hof

Research output: Contribution to journalArticlepeer-review

Abstract

Inflammatory joint diseases such as rheumatoid arthritis are associated with local bone erosions and systemic bone loss, mediated by increased osteoclastic activity. The receptor activator of nuclear factor (NF) κB ligand (RANKL) plays a key role in mediating inflammation-induced bone loss, whereas tumour necrosis factor (TNF) plays a central role in the inflammatory process. Here we tested whether a recently identified class of small molecule inhibitors of RANKL signalling (ABD compounds) also affect TNF signalling and whether these compounds inhibit inflammation in an animal model of rheumatoid arthritis.
Original languageEnglish
Pages (from-to)220-226
JournalAnnals of the Rheumatic Diseases
Volume74
Issue number1
Early online date4 Oct 2013
DOIs
Publication statusPublished - Jan 2015

Fingerprint

Dive into the research topics of 'Identification of small molecule inhibitors of RANKL and TNF signalling as anti-inflammatory and antiresorptive agents in mice'. Together they form a unique fingerprint.

Cite this